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Professional antigen presenting cells (APC), i.e., dendritic cells (DC),
monocytes/macrophages, and B lymphocytes, are critically important in the recognition
of an invading pathogen and presentation of antigens to the T cell-mediated arm of
immunity. Human herpesvirus 8 (HHV-8) is one of the few human viruses that primarily
targets these APC for infection, altering their cytokine profiles, manipulating their surface
expression of MHC molecules, and altering their ability to activate HHV-8-specific T cells.
This could be why T cell responses to HHV-8 antigens are not very robust. Of these APC,
only B cells support complete, lytic HHV-8 infection. However, both complete and abortive
virus replication cycles in APC could directly affect viral pathogenesis and progression to
Kaposi’s sarcoma (KS) and HHV-8-associated B cell cancers. In this review, we discuss the
effects of HHV-8 infection on professional APC and their relationship to the development
of KS and B cell lymphomas.
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INTRODUCTION
Human herpesvirus 8 (HHV-8) or Kaposi’s sarcoma (KS)-
associated herpesvirus, is the etiologic agent of KS (Chang et al.,
1994), a neoplasm of endothelial origin that occurs in four dis-
tinct epidemiologic forms (Dedicoat and Newton, 2003; Jessop,
2006): classic or Mediterranean KS, epidemic or AIDS-related
KS, endemic or African KS, and iatrogenic or organ transplant-
associated KS. KS is the most common cancer associated with
HIV-1 infection and AIDS (Cohen et al., 2005). Although the
incidence of KS in HIV-1 infected persons declined with the
advent of antiretroviral therapy (ART) (Gallafent et al., 2005),
KS can occur in persons on ART with suppressed HIV-1 infec-
tion (Maurer et al., 2007). The success of ART in treating
HIV-1-associated KS has also been countered by the occasional
occurrence of an immune reconstitution inflammatory syndrome
(Feller et al., 2008). This is a severe, temporary enhancement of
KS lesions due to an increase in inflammation and immunologic
recovery after ART.
The discovery of HHV-8 and its causal role in KS develop-
ment opened the potential for prophylaxis and treatment of the
infection and cancer with antiviral drugs, and prevention of both
with a vaccine. Strategies to achieve these ends require an intimate
knowledge of the pathogenesis and immune control of HHV-8
infection. We postulate that host control of HHV-8 infection and
development of KS is linked to T cell interactions with HHV-8
infected, professional antigen presenting cells (APC), i.e., den-
dritic cells (DC), monocytes/macrophages, and B lymphocytes.
Similarly, APC-T interactions are likely to be centrally involved in
the HHV-8-associated B cell neoplasms multicentric Castleman’s
disease (MCD) (Soulier et al., 1995) and primary effusion lym-
phoma (PEL) (Cesarman et al., 1995; Nador et al., 1996). This
review covers various aspects of HHV-8 targeting of APC and
T cell responses in host control of this infectious and oncogenic
process.
HHV-8 has been reported to be transmitted to common mar-
mosets and cause persistent infection with rare, KS-like skin
lesions (Chang et al., 2009). However, there is as yet no consensus
that this or other simian models (Jung et al., 1999; Fickenscher
and Fleckenstein, 2001; Rosenwirth et al., 2011) recapitulate
human HHV-8 infection and development of KS or other cancers
associated with this herpesvirus. Thus, although in vitro models
are suspect to lacking certain in vivo characteristics, we will focus
in this review on HHV-8 infection of human APC as being the
most relevant to this human species-specific herpesvirus.
HHV-8 INFECTION OF PROFESSIONAL APC
As with the other human gamma herpesvirus, Epstein Barr virus
(EBV) (Ning, 2011), HHV-8 targets APC both in vivo and in vitro.
Indeed, the primary tropism of B cells by these gamma her-
pesviruses is uncommon among human virus infections. This
sets the stage for development of their associated cancers both
indirectly, through alteration of host immunity dependent on
APC function, and directly via neoplastic effects of the virus.
HHV-8 infection within KS tumors is primarily found in spin-
dle cells, which are of mixed vascular and lymphatic endothelial
cell and macrophage origin (Regezi et al., 1993; Bubman and
Cesarman, 2003). However, HHV-8 is also detected in monocytes
that are found in proximity to KS lesions, and circulating B cells
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of KS patients (Blasig et al., 1997; Monini et al., 1999). In PEL,
HHV-8 is found in immunoblastic cells expressing plasma cell
markers, and in plasmablastic cells of a less terminally differen-
tiated state in MCD (Du et al., 2007). The intimate association
of HHV-8 with such professional APC in the KS lesion and
in other HHV-8-associated cancers suggests a major role for
virus-APC interplay. Moreover, anti-HHV-8 T cell immunity that
presumably is critically dependent on such virus-APC interac-
tions, is present in HIV-1 infected and uninfected persons who
are seropositive for HHV-8 (Robey et al., 2010). Achieving a bet-
ter understanding of the role of HHV-8 in inducing-associated
cancers could greatly benefit from a yet-to-be-developed in vitro
model of primary HHV-8 infection of a natural target cell. This
model should consistently reflect HHV-8 lytic, latent, and reacti-
vation infections. HHV-8 infection of APC could provide such a
model.
HHV-8 RECEPTORS ON APC
Infection of APC in vitro reveals different cycles of HHV-8 repli-
cation that are likely to relate to pathogenesis of the virus.
HHV-8 initially targets cell surface receptors for infection, which
represent the first level of APC alteration. Herpesviruses use
more than one receptor to infect the same cell (Heldwein and
Krummenacher, 2008). Use of these receptors by herpesviruses is
hierarchical, based largely on differential expression of the recep-
tors in specific cell types and states of cell activation. Extensive
in vitro evidence indicates that the ubiquitous cell surface pro-
teoglycan, heparan sulfate, serves as an initial binding receptor
for HHV-8 on endothelial cells and fibroblasts, as well as APC
(Akula et al., 2001b, 2002; Chandran, 2010; Kerur et al., 2010).
Multiple integrins are subsequently involved in HHV-8 binding
and entry (Kerur et al., 2010). A third level of differential selec-
tion has been identified from in vitro studies of the three major
types of professional APC. The type II C-type lectin, DC-specific
ICAM-3 grabbing nonintegrin (DC-SIGN; CD209) serves as a
receptor for HHV-8 on both DC and B cells (Rappocciolo et al.,
2006, 2008). Recently a new entry receptor for HHV-8 has been
discovered on endothelial and epithelial cells (Hahn et al., 2012),
i.e., ephrin receptor tyrosine kinase A2. This tyrosine kinase func-
tions in neovascularization and oncogenesis, and has not yet been
assessed in HHV-8 infection of APC.
The role of HHV-8 binding to APC receptors for entry and
infection is being clarified with accumulating evidence that cer-
tain C-type lectins and integrins are essential to this process.
For example, the Raji B lymphoblastoid cell line (LCL) and
the myeloblastoid K562 erythroleukemia cell line constitutively
express little or no DC-SIGN or α3β1 integrin (Rappocciolo et al.,
2006). Thus, these cell lines do not support detectable produc-
tion of HHV-8 virions (Blackbourn et al., 2000b; Bechtel et al.,
2003; Rappocciolo et al., 2006). However, transfection of the cell
lines with DC-SIGN renders them highly permissive for HHV-8
infection as measured by production of viral proteins and DNA
(Rappocciolo et al., 2006). Moreover, infection of these cell lines
can be blocked by anti-DC-SIGN mAb, soluble DC-SIGN, and
mannan, a natural ligand of DC-SIGN. Interestingly, four B cell
lines (BJAB, Ramos, BCBL1, JSC1) and two T cell lines (Jurkat
and SupT1) are susceptible to infection through cell-mediated
transmission with a doxycyline (DOX)-inducible cell line har-
boring recombinant HHV-8 (rKSHV.219) (Myoung and Ganem,
2011c). This indicates that viral entry can be achieved despite
lack of expression of a major HHV-8 receptor. There is also evi-
dence that HHV-8 can infect CD34+ stem cell precursors of DC
in vitro by as yet undefined receptors (Henry et al., 1999; Larcher
et al., 2005). It is likely that there are less prominent alternative
receptors for HHV-8 that account for a small percentage of DC-
SIGN negative APC and cell lines that can be infected by this
virus.
B CELL INFECTION WITH HHV-8
Suggestive evidence that HHV-8 is B-cell tropic in vivo is that
HHV-8 DNA is detected in B cells from patients with KS
lesions (Ambroziak et al., 1995) and some HIV-1/HHV-8 coin-
fected individuals (Murayama et al., 1994). Further evidence
that HHV-8 targets B cells is the isolation of immortalized B
cell lines from patients with PEL that are infected with HHV-8
(Cesarman et al., 1995). The first in vitro evidence that HHV-8
can infect B cells was that virus produced by these PEL cell lines
could be transmitted to neonatal cord blood B cells (Mesri et al.,
1996). We speculate that the lack of further evidence for B cell
infection in those early years was that such infection requires DC-
SIGN expression that is enhanced by an activated state in B cells.
Thus, we showed that once blood-derived B cells are activated
to express DC-SIGN, HHV-8 can effectively establish infection
and elicit full-cycle production of infectious virions in these cells
(Rappocciolo et al., 2008).
The fact that HHV-8 cannot infect Raji LCL or K562 cells
expressing DC-SIGN that lacks its transmembrane domain sup-
ports that viral entry requires DC-SIGN-mediated endocytosis.
Moreover, infection can be blocked by pretreatment of B cells
with anti-DC-SIGN monoclonal antibody (mAb) or mannan,
but not Ab specific for the amino acid transporter protein xCT
(Rappocciolo et al., 2008). HHV-8 has been reported to use
xCT for infection of surface adherent human cells (Kaleeba and
Berger, 2006) and in a post-entry stage of human endothelial cell
infection as part of a complex of heterodimeric membrane gly-
coprotein CD98 and the α3β1 and αVβ3 integrins (Veettil et al.,
2008).
Notably, HHV-8 infection is not restricted to blood-derived B
cells, as tonsillar B cells constitutively express DC-SIGN and can
be lytically infected with the virus in vitro (Rappocciolo et al.,
2008; Myoung and Ganem, 2011a). It is probable that B cells in
such inflamed tonsillar tissue are in an endogenously activated
state, resulting in enhanced expression of DC-SIGN.
The in vitro activated, B cell model for measuring HHV-8
infectivity and replication supports the concept that DC-SIGN is
a major receptor for this virus (Rappocciolo et al., 2006, 2008;
Chandran, 2010). This adds to the wealth of evidence that shows
that, in contrast to previous reports (Ganem, 2007), DC-SIGN
is required for highly efficient infection of natural APC tar-
gets with HHV-8. This is in addition to certain integrins that
are also involved in HHV-8 entry (Akula et al., 2001a,b, 2002;
Birkmann et al., 2001; Veettil et al., 2008). However, there is
still need for improved reliable, quantitative measures of HHV-8
replication to better define B cell infection. These should include
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combinations of real time polymerase chain reaction (PCR)
assays for cell-associated and non-cell-associated copy numbers
of HHV-8 encapsidated DNA, flow cytometry assays for enu-
merating the number of monoclonal Ab (mAb)-stained cells
expressing viral lytic and latency cycle proteins, and most impor-
tant, cell culture-based assays for quantitating the number of
infectious virus particles, e.g., a 50% tissue culture infectious
dose assay. It is remarkable that almost 20 years after discovery
of HHV-8 we do not have such basic assays to study the virus.
It is postulated that HHV-8 infection drives B cells to an
early plasmablast-like state in MCD and a preterminal plasma
cell stage of differentiation in PEL (Frizzera et al., 1983; Miller
et al., 1984; Cesarman et al., 1995; Nador et al., 1995; Agematsu
et al., 1997; Matolcsy et al., 1998; Dupin et al., 2000; Du et al.,
2001; Klein et al., 2003; Chadburn et al., 2004, 2008; Hassman
et al., 2011). Hassman et al. (2011) recently showed that latency-
associated nuclear antigen (LANA)+ B cells express IgM and
the λ light chain at 2.5–3.5 days post-HHV-8 infection in vitro.
These cells are plasmablast-like with increased interleukin (IL) 6
receptor expression and increased proliferative response to IL-6,
with 7–36% expressing CD27. This molecule is a member of
the tumor necrosis factor (TNF)-receptor superfamily, and is
involved in regulation of B cell activation. It is not knownwhether
HHV-8 directly infects these IgM+ memory B cells or a precur-
sor of these cells. Also, there are no data on which subset of B
cells supports a complete lytic cycle of replication with virion
formation and death of the cell. Likewise, there is the possibil-
ity that HHV-8 infection in these B cell subsets results in an
abortive replication cycle, leavingmemory B cells that survive and
maintain latent virus infection. We speculate that HHV-8 infec-
tion of naïve and IgM memory B cells leads to establishment
of latency in a portion of cells, resulting in virus-driven plas-
mablast differentiation, while some cells support the viral lytic
cycle (Figure 1).
FIGURE 1 | HHV-8 targets B cell subpopulations for infection. The
B cell target for HHV-8 infection is unknown. However, evidence
suggests that naïve and/or IgM memory B cell subsets are susceptible
to HHV-8 infection. HHV-8 is endocytosed after binding to cell surface
entry receptors. The virus then enters latency (left) or initiates lytic
replication (Rappocciolo et al., 2008). Latently infected cells drive
differentiation toward a plasmablast phenotype that is responsive to the
proliferative cytokine, IL-6. The alternative pathway is the entry of HHV-8
into the lytic cycle to begin transcription of lytic-associated proteins in
activated B cells (red outline). The lytic cycle may stop prior to virion
production, resulting in an abortive replicative cycle as seen in DC,
endothelial cells, and fibroblasts. The virus in these cells likely enters
latency or may result in B cell apoptosis. Some cells, however, will
support full lytic cycle replication, resulting in lytic protein synthesis, and
increases in viral DNA that correspond to infectious HHV-8 progeny and
subsequent release through cell lysis.
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Currently, the main in vitro models that recapitulate HHV-8
infection of APC are B lineage cell lines persistently infected with
the virus. Among them, the body cavity-based lymphoma cell line
(BCBL-1), a B cell line derived from a patient with PEL which
is latently infected with HHV-8 and EBV negative (Chang et al.,
1994; Cesarman et al., 1995), is the most commonly utilized. In
latently infected cells of KS tumors and in such cell line mod-
els, the virus exists as circular or episomal DNA with limited
expression of latent genes (Schulz, 2006). Therefore, HHV-8 lytic
and latent infections cannot be defined conventionally in these
systems starting with the total absence of infectious viral parti-
cles, as there is always a low level of persistent virus production.
However, latency can be disrupted, triggering the lytic cascade of
viral replication, and lytic genes expressed sequentially as imme-
diate early (IE) genes, early (E) genes, and late (L) genes, resulting
in production of encapsidated virions. Such lytic viral replica-
tion is largely irreversible (Chandran, 2010; Wen and Damania,
2010).
HHV-8 lytic gene profiling in these persistently infected PEL
cell lines has been extensively accomplished using tiling microar-
ray (Chen et al., 2009), DNA microarray (Agematsu et al.,
1997; Chandriani et al., 2010; Lock et al., 2010), and high-
throughput real-time PCR (Fakhari and Dittmer, 2002; Dittmer,
2003). However, most studies on latency-lytic reactivation of
HHV-8 use various chemicals to induce viral replication (Myoung
and Ganem, 2011b). The question is whether such reactivation
reflects natural HHV-8 viral lytic reactivation from latency, since
chemical agents such as 12-O-tetradecanoylphorbol-13-acetate
(TPA) have pleiotropic effects on host cell signaling and chro-
matin structure. How they affect cell signaling pathways is also
unknown. Thus, the natural reactivated cascade of lytic tran-
scripts of HHV-8 still waits to be revealed.
Instead of using chemical inducers, Nakamura et al. (2003)
developed an engineered BCBL-1 cell line that inducibly expresses
the replication transactivator protein, RTA, encoded by ORF50,
i.e., TREx-BCBL1-RTA. RTA is necessary and sufficient for the
switch between HHV-8 latency and lytic replication (Deng et al.,
2000). In fact, mutation of the RBP-Jk sites within the RTA pro-
moter is enough to enhance latency in transformed-293 cells
and peripheral blood mononuclear cells (PBMC) (Lu et al.,
2012). In the TREx-BCBL1-RTA cell line, RTA expression is
under the control of a DOX-inducible promoter. Treatment of
TREx-BCBL1-RTA cells with DOX results in expression of RTA,
which in turn induces viral replication (Nakamura et al., 2003).
While the role of RTA in causing a switch from latency to
viral replication has been demonstrated, the mechanisms regu-
lating coordinate induction of expression of most of the HHV-8
lytic genes during this reactivation have not been evaluated in a
systematic fashion.
Virus reactivation events have been studied in primary and
immortalized microvascular endothelial cells (MVEC) with the
recombinant virus, rKSHV.219 (Vieira and O’Hearn, 2004). This
virus expresses a green fluorescent protein (GFP) under an EF-1α
promoter to indicate infection and a red fluorescent protein under
a PANpromoter to indicate lytic transcription. This model should
be considered for amore detailed evaluation of APC infection and
reactivation.
Transcription of HHV-8 lytic genes occurs during either a
primary infection of susceptible cells or during reactivation of
latently infected cells. The question remains whether the kinetic
gene activation in a chemically induced cell line (BCBL-1) or
the naturally targeted RTA (TREx-BCBL1-RTA) will reflect the
cascade events of natural infection of B cells or other APC. To
identify the true gene transcription and reactivation events in
HHV-8 infection, primary cells susceptible to HHV-8 should be
used. Only then can the observations from TPA-induced BCBL-1
and DOX-induced TREx-BCBL1-RTA cell lines be validated.
In 2005, a cluster of microRNA (miRNA) coded by HHV-8
was discovered (Cai et al., 2005; Samols et al., 2005). This short,
22 nucleotide, non-coding miRNA silences mRNA expression
through a silencing complex (miRISC). HHV-8 miRNAs are
expressed during lytic and latency cycles of virus replication, and
act on both cellular and viral transcriptomes (Gottwein, 2012).
Studies of HHV-8 miRNA have utilized PEL cell lines, as well as
foreskin fibroblasts and endothelial cells. These indicate a multi-
factorial role in maintaining viral latency, regulating lytic virus
replication, and enhancing cell survival. As miRNA activity is
dependent on its level and targets within specific cell types, it is
imperative that miRNA be assessed in primary B cells.
Finally, as HHV-8 is one of the few human viruses that primar-
ily targets B cells, an in depth understanding of the effects HHV-8
infection has on these cells should be established. However, lit-
tle data exist concerning B cell activation states or surface marker
expression uponHHV-8 infection. Likewise, interactions between
HHV-8 infected B cells and CD4+ T helper cells are yet to be
defined. Considering that the major function of B cells is produc-
tion of Ab that prevent and ameliorate infection, there is need to
assess the quality and quantity of Ab production over the course
of HHV-8 infection and development of KS. Yet, there is no con-
sensus assay for detecting or titering anti-HHV-8 Ab. Detection
of anti-LANA Ab by immunofluorescence assays has low sen-
sitivity (as low as 64%) among individuals with KS (Rabkin
et al., 1998; Corchero et al., 2001; Nascimento et al., 2007).
ELISA and Western blot assays for anti-latent (LANA) and lytic
(ORF65 or K8.1) Ab have higher sensitivities and are often used
for serologic testing, yet can have low specificities (Nascimento
et al., 2007). These conventional methods for serologic testing
therefore lack standardization and can be unreliable, under-
lining the necessity for more accurate methods of quantifying
anti-HHV-8 Ab.
Regardless of the vagaries of anti-HHV-8 Ab assessments,
humoral immunity to HHV-8 infection has been described for
several cohorts. A luciferase immunoprecipitation system that
quantifies Ab response to multiple antigens was used to compare
profiles of KS, MCD, and PEL patients (Burbelo et al., 2010). The
study showed significant differences in Ab responses among the
groups, including higher anti-K8.1 Ab detected in PEL and MCD
compared to KS and higher Ab titers to ORF65 in PEL compared
to KS. Likewise, higher Ab titers against v-cyclin were observed
in KS and PEL compared to MCD, and higher anti-LANA Ab
titers were detected in KS compared to MCD. An explanation for
the difference in Ab responses in individuals with these HHV-8-
associated cancers is currently unknown, but is likely a reflection
of the differential expression of latent and lytic viral genes. The
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quality and quantity of anti-HHV-8 responsemay change over the
course of disease progression or after anti-viral therapy. Following
ART, increases in Ab against both latent and lytic proteins have
been observed for individuals with or without KS (Gill et al., 2002;
Wilkinson et al., 2002; Bourboulia et al., 2004; Sullivan et al.,
2010). More in depth studies with larger cohorts and advanced
testing methods should be performed, while in vitro models for
HHV-8 infection in B cells and detection of antiviral Ab should
be established.
Interestingly, there are only minimal data on neutralizing Ab
in HHV-8 infection. The first such evidence was that rabbit poly-
clonal neutralizing Ab to gB prevent HHV-8 infection of primary
human foreskin fibroblasts (Akula et al., 2001a) and oral epithe-
lial cells (Duus et al., 2004). Concurrently, it was demonstrated
that sera from persons whowere seropositive for HHV-8 as shown
by anti-LANA immunofluoresence assay also had neutralizing
Ab that inhibited virus infection of transformed dermal MVEC
(Dialyna et al., 2004). Using a recombinant HHV-8 (rKSHV.152)
that expresses GFP, Kimball et al. (2004) found significantly lower
neutralizing Ab titers to HHV-8 in the serum of HIV-1 infected
persons with KS compared to those without KS. This is in contrast
to Inoue et al. (2004) who reported that there were no differences
in neutralizing Ab titers between HIV-1 infected patients with or
without KS. However, the latter study used an HHV-8 reporter
cell line T1H6 treated with polybrene in their virus neutralization
assay. Polybrene results in receptor-independent infection (Davis
et al., 2002), thus potentially obscuring interpretation of virus
neutralization assays. Finally, it is evident that there is a need for
in depth, longitudinal studies of neutralizing Ab and other antivi-
ral Ab such as those that mediate Ab-dependent cell cytotoxicity,
in relation to progression of HHV-8 infection and development
HHV-8 related cancers.
MONOCYTE/MACROPHAGE INFECTION WITH HHV-8
Macrophages in several body compartments naturally express
DC-SIGN (Granelli-Piperno et al., 2005; Kamada et al., 2009),
as well as integrins including α3β1 (Ammon et al., 2000), which
presumably renders them susceptible to HHV-8 infection. An
early report showed that monocyte-derivedmacrophages (MDM)
from normal donors that are stimulated in vitro with allogeneic
PBMC can be infected by HHV-8, but this rarely resulted in com-
plete, lytic replication (Blackbourn et al., 2000b). In addition,
treatment of blood monocytes from KS patients with proinflam-
matory cytokines in vitro results in HHV-8 persistence (Monini
et al., 1999).
MDM become susceptible to HHV-8 infection in vitro after
activation with IL-13, which enhances DC-SIGN expression
(Rappocciolo et al., 2006). IL-13 is an anti-inflammatory, Th2
cytokine that induces alternatively activated (M2) macrophages
(Hao et al., 2012). These contrast with classically activated (M1)
macrophages which have preferential expression of proinflam-
matory cytokines, chemokines, and effector molecules, such as
IL-12, IL-23, tumor necrosis factor α (TNF-α), inducible nitric
oxide synthase (iNOS), and MHC class I and II. In contrast,
M2 macrophages express a wide array of anti-inflammatory
molecules, including IL-10, and transforming growth factor β
(TGF-β). IL-13 also promotes differentiation of B cells into
Ab-secreting plasma cells. M2 macrophages express more DC-
SIGN than M1 macrophages (Cassol et al., 2012), supporting
the concept that M2 macrophages are likely to serve as a more
efficient target cell for HHV-8 infection. Importantly, multiple
receptors are needed for efficient infection of these macrophages
by HHV-8. Indeed, when DC-SIGN is blocked in IL-13-activated
MDM or the monocytic cell line THP-1, HHV-8 can still bind
using heparan sulfate, although virus entry is reduced (Kerur
et al., 2010).
Although studies are lacking for coordinated expression of
HHV-8 ORFs in monocytes/macrophages, HHV-8 establishes
productive infection in THP-1 cells with an ordered expression
of latency gene ORF73 and lytic gene ORF50. In fact, the HHV-8
genome was reported to persist for 30 days in these cells (Kerur
et al., 2010). Such limited expression of lytic genes together with
the persistence of latency genes is believed to be unique for
HHV-8 (Krishnan et al., 2004).
Of interest is that ORF K14 of HHV-8 encodes a surface
glycoprotein vOX2 that is homologous to cellular OX2 (Chung
et al., 2002), and which inhibits macrophage function (Foster-
Cuevas et al., 2004). The vOX2 glycoprotein could be central
to HHV-8 immunopathogenesis in that it stimulates production
of inflammatory cytokines IL-1β, IL-6, monocyte chemoattrac-
tant protein 1 (MCP-1), and TNF-α in primary monocytes,
MDM, and monocyte-derived DC (MDDC) (Chung et al., 2002).
Furthermore, expression of vOX2 on B cells stimulates monocytes
to produce inflammatory cytokines. MDM transfected with vOX2
produce inflammatory cytokines and have enhanced phagocytic
activity, while inhibiting the immunomodulatory effects of IFN-
γ and down-regulating MHC class I and class II expression
on macrophages (Salata et al., 2009). It was recently reported
that vOX2-transfected APC co-cultured with T cells results in
suppressed IFN-γ production and mobilization of the cytolytic
granule marker CD107a through inhibition of ERK1/2 phospho-
rylation (Misstear et al., 2012).
HHV-8 INFECTION OF MYELOID DC
Evidence of infection of human DC in vivo with HHV-8 has
been limited (Rettig et al., 1997; Olsen et al., 1998). However,
there is no a priori reason why human DC should not take up
HHV-8 and support at least abortive infection in vivo. Tissue resi-
dent, myeloid DC constitutively express DC-SIGN (Soilleux et al.,
2002). MDDC express DC-SIGN in vitro, again indicating a cen-
tral role for this receptor in HHV-8 infection of APC. Studies are
needed to determine whether this C-type lectin is required for
HHV-8 infection of tissue DC in vivo.
WhenMDDC are infected in vitro with HHV-8, viral lytic pro-
teins are produced with little viral DNA production (Rappocciolo
et al., 2006), similar to abortive HHV-8 infection of vascular
endothelial cells (Renne et al., 1998; Vieira et al., 2001; Akula
et al., 2002; Naranatt et al., 2003; Raghu et al., 2009). Although
HHV-8 infection does not significantly alter MDDC viability,
it decreases MDDC function, i.e., lowers their capacity to acti-
vate antigen-specific CD8+ T cell responses. Moreover, HHV-8
infected MDDC have impaired antigen uptake, with a signif-
icant decrease in endocytic capacity and DC-SIGN expression
within 24 h after infection. DC-SIGN internalization in MDDC
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is associated with lytic HHV-8 gene expression (Rappocciolo
et al., 2006). In addition to MDDC, HHV-8 in vitro infec-
tion of IL-13-treated MDM results in a loss of DC-SIGN sur-
face expression, suggesting that HHV-8 binding to DC-SIGN
triggers internalization. Hence, alteration of DC-SIGN expres-
sion could be a strategy used by HHV-8 to escape immune
defenses and lead to a non-robust immune response (Wang et al.,
2002).
HHV-8 INFECTION OF LANGERHANS CELLS (LC) AND
INTERSTITIAL-DERMAL DC (iDDC)
The skin and mucosa contains two major types of DC: (1) langer-
hans cells (LC), which reside in the epidermis in close contact with
keratinocytes and (2) interstitial-dermal DC (iDDC), resident in
the dermis and mucosal layers. LC and iDDC process cutaneous
antigens and migrate to draining lymph nodes to present anti-
gens to T and B cells. Because of the strategic position of LC and
iDDC and their ability to capture pathogens, these cells could rep-
resent potential targets for HHV-8 infection. Furthermore, due
to the expression of the C-type lectins, i.e., langerin (CD207)
and DC-SIGN, on LC and iDDC, respectively, it is tempting
to speculate that HHV-8 could utilize the same entry mecha-
nisms as seen in MDDC (Rappocciolo et al., 2006). Therefore,
it is important to determine if these APC are also targeted by
HHV-8 and whether they support full lytic replication or an
abortive cycle. LC and iDDC can be generated from pluripo-
tent cord blood CD34+ cells (Caux et al., 1997), which could
prove to be valuable tools to study HHV-8 infection and subse-
quent antigen process and presentation to T cells (Colleton et al.,
2009).
HHV-8 INFECTION OF PLASMACYTOID DC (pDC)
Plasmacytoid DC (pDC) are a lymphoid-lineage subset of APC
that produce extraordinary amounts of the antiviral protein
interferon α (IFN-α) in response to virus infection (Liu, 2005).
Although pDC do not express DC-SIGN, they are susceptible to
in vitro infection with GFP-tagged HHV-8 (West et al., 2011).
GFP expression was detected in 23% of pDC from healthy blood
donors at 16 h post-infection. Also, ORF57 and LANA expres-
sion was detected by PCR at 48 and 72 h, respectively. Infection
of the pDC results in upregulation of activation molecule CD83
and T cell co-receptor CD86, and induces production of IFN-α.
Induction of IFN-α by HHV-8 occurs through activation of Toll-
like receptor 9 (TLR9) signaling in pDC. At present, however, it is
unclear what receptors HHV-8 uses to infect pDC, and whether
HHV-8 infection of pDC results in an abortive or fully lytic viral
replicative cycle.
HHV-8 INFECTION AND TLR
Several types of TLR expressed on different APC are emerg-
ing as important factors in the innate and adaptive immune
response to HHV-8. Notably, virus triggering of C-type lectins,
including DC-SIGN, in combination with TLR triggering on DC
induces signaling and cytokine responses. These in turn regu-
late T cell polarization that is central to host immune control
of infections (Van Kooyk, 2008). In addition, TLR have also
been implicated in reactivation of HHV-8. TRL7/8 could control
reactivation of HHV-8 from latency in B cells. That is, ago-
nists specific for TLR7/8 reactivate latent HHV-8 and induce
viral lytic gene transcription and replication in latently infected
PEL cell lines of B cell origin (Gregory et al., 2009). This has
important implications for host control of HHV-8 infection,
as signaling through the TLR1/2/6 complex, TLR7, TLR9, and
TLR10 affects multiple stages of B cell activation, proliferation,
cytokine secretion, terminal differentiation, and Ab secretion in
response to T cell-dependent antigens (Bekeredjian-Ding and
Jego, 2009).
SUMMARY
Utilizing heparan sulfate, cell surface integrins, and DC-SIGN for
binding and entry, HHV-8 establishes infection in professional
APC that are essential to processing and presenting antigen. As
these HHV-8-targeted APC initiate T and B cell adaptive immune
responses, this could demonstrate an evolutionary mechanism to
establish viral latency and persistence in the host. Accordingly,
regulation of viral protein expression limits detection of HHV-8
in APC by T cells, resulting in sustained latency. Although valu-
able conclusions have been drawn from immortalized cell lines
as surrogates for these APC, primary cell models such as blood
and tissue APC provide a more natural account of the qual-
ity of HHV-8 infection, better displaying the mechanisms of
latency and abortive and non-abortive virus replicative cycles.
This is reflected by the fact that among professional APC, HHV-8
undergoes full lytic replication only in activated B lymphocytes,
yet can bind to, enter and alter various functions of DC and
monocytes/macrophages.
CYTOKINES AND CHEMOKINES IN HHV-8 INFECTION OF APC
Cytokines and chemokines produced by inflammatory APC, as
well as T cells, play a crucial role in HHV-8 replication and devel-
opment of KS. Inflammatory changes occur early in KS prior to
the detection of the cancer (Mesri et al., 2010). Proinflammatory
processes drive early stage KS to develop into mature, spin-
dle cell lesions (Rezaee et al., 2006). Thus, KS tumors are
comprised of spindle-shaped cells of endothelial origin (Regezi
et al., 1993) in an environment rich in inflammatory cell infil-
trates, including B cells, monocytes/macrophages, and CD8+ T
cells (Monini et al., 1999). The infiltrating cells produce large
amounts of Th1 polarizing, proinflammatory cytokines (e.g.,
IFN-γ, IL-1β, TNF-α and IL-6), chemokines (e.g., IL-8), and
growth factors [e.g., vascular endothelial growth factor (VEGF)],
which can induce the KS-like phenotype observed in activated
endothelial cells (Fiorelli et al., 1998; Monini et al., 1999; Ensoli
et al., 2000). IFN-γ is the earliest and most abundant inflamma-
tory cytokine observed in KS (Fiorelli et al., 1998) and can be
detected in KS lesions before evidence of HHV-8 DNA (Monini
et al., 1999). IL-6 is also found at very high levels in both KS
lesions and in circulation of patients with MCD (Ambroziak
et al., 1995). In MCD, IL-6 induces B cell proliferation and
causes inflammatory clinical symptoms (Schulte and Talat, 2010).
Observations from a transgenic mouse model demonstrate that
mice expressing viral IL-6 but lacking mammalian IL-6 do
not experience phenotypic changes (e.g., lymphoadenopathy,
hypergammaglobulinemia, splenomegaly) associated with MCD
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(Suthaus et al., 2012). IL-6, as well as oncostatin M (OSM) and
IL-10, are also detected at high levels in PEL cells. Proliferation
of PEL can be inhibited when receptors for the IL-6 path-
way are blocked (Drexler et al., 1999). Thus, an as yet mini-
mally detailed imbalance in the Th1-Th2 milieu during HHV-8
infection appears to be closely linked to APC in driving the
outgrowth of KS endothelial cells, as well as PEL and MCD
B cells.
Other cytokines and chemokines produced by APC, partic-
ularly IL-8 and MCP-1, are elevated in serum of KS patients
and have been implicated in many cancers (Sun et al., 2006;
Mehrad et al., 2007). Enhanced expression of MCP-1, but not
other NF-kβ activated cytokines (RANTES, IL-8 and TNF-α), is
also detected in in vitro infected human umbilical vein endothe-
lial cells (HUVEC) (Caselli et al., 2007). When bound to its
CCR2 receptor on endothelial cells, MCP-1 results in chemo-
taxis and mediates angiogenesis in vitro (Galvez et al., 2005;
Mehrad et al., 2007). KS tumors are highly vascularized with
abnormal angiogenesis, leading to enhanced blood flow to the
tumor by expanding pre-existing blood vessels (Mesri et al.,
2010). IL-1β, TNF-α, IL-8, and IL-6 can also enhance tumor
cell growth and vascularization (Ensoli et al., 1989; Ensoli and
Sturzl, 1998; Fiorelli et al., 1998) by inducing the expression of
two angiogenic mediators, i.e., VEGF and fibroblastic growth
factor (Ensoli et al., 1989; Cohen et al., 1996; Cornali et al.,
1996; Monini et al., 1999). In addition to angiogenesis, inflam-
matory cells and cytokines can contribute to viral reactivation
and replication. IFN-γ was shown to induce ORF59 expression
in BCBL-1 (Blackbourn et al., 2000a) and reactivate latent HHV-
8 in BC-3 PEL cells by activation of Pim-family kinases (Cheng
et al., 2009). Mercader et al. showed OSM, IFN-γ, and hepato-
cyte growth factor/scatter factor-induced lytic cycle activation of
BCBL-1 resulting in virion production (Mercader et al., 2000).
This principle has been demonstrated in HHV-8 infected PBMC,
where inflammatory cytokines could maintain or increase viral
load up to 10-fold when the infected cells were cultured in the
presence of inflammatory cytokines (Monini et al., 1999).
In AIDS-related KS, immune dysregulation and induction
of inflammatory cytokines acts to further enhance KS tumor
growth. When BCBL-1 cells that are latently infected with
HHV-8 are cultured with HIV-1 infected CD4+ T cells, sol-
uble factors secreted by the T cells cause the virus to enter
lytic reactivation (Mercader et al., 2000). Inflammatory cytokines
induced by both HIV-1-infected and HHV-8-infected cells pro-
mote expression of receptors for HIV-1 Tat, which acts as a
progression factor in KS development (Ensoli et al., 1990; Barillari
et al., 1993) and increasing viral load (Harrington et al., 1997).
Indeed, serum and cell samples taken from KS lesions of HIV-1
infected individuals co-infected with HHV-8 show markedly
increased levels of inflammatory cytokines, growth factors, and
angiogenic mediators (Ensoli and Sturzl, 1998; Pugliese et al.,
2002).
HHV-8 has a broad cellular tropism in vivo including B
cells, endothelial cells, monocytes, keratinocytes, and epithelial
cells that could result in production of inflammatory medi-
ators (Chakraborty et al., 2012). In pDC, HHV-8 induces
enhanced levels of IL-6, IL-8, MIP-1α, MIP-1β, CCL22, and
IFN-α (West et al., 2011). In monocytes, production of IP-10,
IFN-β1, MCP-1, and IRF-1 occurs in conjunction with an upreg-
ulation of TLR3 expression (West and Damania, 2008). Our
lab has previously demonstrated that MDDC infected in vitro
with HHV-8 secrete IL-6, TNF-α, IP-10, MIP-1α, and MIP-1β
(Hensler et al., 2009). While IL-12p40 expression increases post-
infection, bioactive IL-12p70 is not detected in HHV-8 infected
MDDC. This suggests a virus-related inhibition of constitutive
production of IL-12p35, or a defect in complexing of these
subunits into IL-12p70. Furthermore, the results support an
intentional skewing of cytokine production in HHV-8-infected
MDDC toward induction of a Th2 response that could enhance
development of KS.
We speculate that cytokine and chemokine profiles in HHV-8
infected B cells is similar to the cytokine dysregulation observed
in EBV-associated disease (Gosselin et al., 1992; Klein et al., 1996;
Kurzrock, 2001; Glaser et al., 2006). Elevated levels of IL-1β,
TNF-α, IL-6, IL-8, and IL-10 are detected in the serum of patients
with EBV-associated diseases, while a less favorable outcome
correlates with increases of IL-6 and IL-10 in Hodgkin’s lym-
phoma (Fayad et al., 2001). Common strategies between EBV and
HHV-8, such as NF-κB signaling pathway alterations (Hayden
and Ghosh, 2008; De Oliveira et al., 2010) and the expression
of virokines (Sin and Dittmer, 2012), imply that an imbalance
of immune mediators is associated with the oncogenesis of these
gammaherpesviruses.
HHV-8 ENCODED PROTEINS INVOLVED IN IMMUNE MEDIATOR
RESPONSES
Besides cellular cytokines and chemokines, HHV-8 encodes sev-
eral proteins that share homology to host genes. These are
involved in inflammation and angiogenesis that contribute to
the inflammatory environment observed in KS. Cytokines and
chemokines encoded by HHV-8 have been the focus of numer-
ous studies and reviews (Nicholas, 2005; Gasperini et al., 2008;
Mesri et al., 2010; Sakakibara and Tosato, 2011; Lee et al., 2012;
Sin andDittmer, 2012). Thus, vIL-6 has 24% homology to human
IL-6 and can induce expression of VEGF and MCP-1 (Nicholas
et al., 1997). These in turn trigger angiogenic pathways. Elevated
levels of vIL-6, as well as levels of human IL-6 and HHV-8 viral
load, have been associated with a recently described syndrome
of severe systemic inflammatory symptoms (Uldrick et al., 2010).
However, consistently reproducible assays for quantitation of vIL6
are needed to extend such studies.
The G-protein coupled receptor (vGPCR) is an early
lytic phase gene homologous to the IL-8 receptor, CXCR-2
(Arvanitakis et al., 1997; Nicholas, 2005). vGPCR constitutively
signals and results in enhanced production of IL-1β, IL-8, MCP-1,
IL-6, and VEGF that can have both autocrine and paracrine
effects (Gershengorn et al., 1998; Schwarz and Murphy, 2001).
K1 and K15 are signal transducing proteins that induce VEGF,
IL-6, and IL-8 (Choi and Nicholas, 2010). LANA and the viral
flice inhibitory proteins (vFLIP) have been linked to enhanced
cytokine production via activation of the MAPK andNF-κB path-
ways, respectively (Wang and Boshoff, 2005). vIRF3 expression
inhibits MHC class II expression as well as IFN-γ production
(Schmidt et al., 2011). Finally, viral macrophage inflammatory
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proteins (MIPs) (vCCL1, vCCL2, vCCL3) share homology to
MIP1-α and RANTES and can induce monocyte chemotaxis and
signal transduction (Arvanitakis et al., 1997; Nakano et al., 2003;
Nicholas, 2005). Given the plethora of such data derived from
highly manipulated molecular and cell line models, the challenge
is to link these unique HHV-8 factors directly to HHV-8 infec-
tion and development of cancers in natural cellular targets of the
virus.
SUMMARY
A delicate balance exists between protective immunity involving
cytokine and chemokine production by host APC and virus-
driven induction of cytokines and chemokines that aid in the
dissemination of infection and mediate pathogenesis. Several of
the mediators that are essential to the immune response and acti-
vation of lymphocytes can exacerbate infection and cause clinical
symptoms when over produced in response to HHV-8 infec-
tion, including IFN-γ, IL-1β, IL-6, IL-8, TNF-α, and MCP-1.
The role of each cytokine/chemokine in the development of KS
and the inflammatory environment observed within KS tumors
likely varies depending on their quantity and origin. Therefore,
production of these immune mediators by cells the virus nat-
urally targets for infection may better reflect HHV-8-induced,
cytokine/chemokine driven pathogenesis.
APC-T CELL INTERACTIONS IN HHV-8 INFECTION
Given our rudimentary understanding of HHV-8-APC interac-
tions, we know even less regarding HHV-8-specific T cell-APC
interactions and their role in controlling viral infection and dis-
ease. A key challenge is to adapt current in vitro models using cell
lines and HHV-8 constructs to systems that allow deciphering of
the basic steps of natural HHV-8 infection, and antigen process-
ing and presentation, in various types of APC. The interactions
of APC with T cells that underlie the generation of anti-HHV-
8 T cell immunity begin with DC of myeloid origin that take
up viral antigen at local sites of infection, then travel to the
draining lymphatics, and induce antiviral T cell responses (Ueno
et al., 2007). There are specialized subsets of DC that populate
different tissue sites and have distinct virologic interactions and
immunologic functions. Myeloid-derived LC and iDDC populate
the epidermis and dermis respectively, and are associated with KS
lesions. iDDC are similar in phenotype and function to dermal
DC, and are linked to systemic KS lesions. Other DC subsets such
as CD141+ DC which are the human surrogates of mouse CD8α
DC subsets (Bachem et al., 2010; Jongbloed et al., 2010), could
be natural targets for HHV-8. These cells exhibit strong priming
of T cells to antigen. It is imperative that we assess transcription
of HHV-8 ORFs in natural targets of the virus, in comparison
to well-documented immunomodulatory properties of HHV-8
expressed in cell lines and artificial constructs, such as persistently
infected BCBL-1 (Coscoy, 2007).
Interactions of HHV-8 with DC subsets could be critical at
the site of virus replication, and be centrally involved in gener-
ating T cell responses to the virus. Efficient activation of HHV-8
epitope-specific CD8+ T cells requires presentation by peptide-
loaded, autologous, mature DC (Wang et al., 2002). This is similar
to optimal activation of anti-EBV CTL by peptide-loaded DC
(Wheatley et al., 1998; Redchenko and Rickinson, 1999; Subklewe
et al., 1999a,b, 2001, 2005; Lin et al., 2002). Other studies have
revealed polyfunctional CD8+ and CD4+ T cell reactivity and
new MHC class I epitopes for HIV-1 Gag and Nef using peptide-
loaded DC (Huang et al., 2010). Importantly, we have used this
DC model to map epitopes of HHV-8 lytic and latency pro-
teins with libraries of synthetic, 15mer peptides overlapping by
11aa (Lepone et al., 2010). Nevertheless, it may be more prac-
tical to generate large numbers of CD40L-activated, autologous
B cells that favorably compare to DC as APC (Schultze et al.,
2004).
To date, relatively few CD8+ and CD4+ T cell epitopes
within only 15 of the over 80 ORFs of HHV-8 have been
identified, and most of these are restricted by HLA A∗0201
(Robey et al., 2010). Information is therefore needed on the
broad range of potential antigenic sites in the virus that are
restricted by other MHC class I and II haplotypes. Moreover,
no studies have yet established a hierarchy of naïve and mem-
ory CD8+ or CD4+ T cell responses to HHV-8 epitopes in
control of HHV-8 infection. There also are minimal data on
whether alterations in anti-HHV-8 T cell responses are related
to development of KS (Guihot et al., 2006) and whether the
lower incidence of KS in HIV-1 infected persons receiving ART is
related to increases in anti-HHV-8 T cell responses (Bourboulia
et al., 2004; Bihl et al., 2007a). Such information is important
for development of prophylactic and therapeutic vaccines for
HHV-8.
HHV-8 infection alters the capacity of DC to be recognized
by and activate CTL. Both direct presentation using viral proteins
endogenously produced in DC, and cross-presentation pathways
using viral proteins from exogenous sources of virus are likely to
be operative in HHV-8 infection. In fact, EBV does not replicate
in MDDC, which instead activate anti-EBV CD8+ T cells by an
antigen cross-presentation pathway (Herr et al., 2000; Subklewe
et al., 2001; Popescu et al., 2003).
It is possible that HHV-8 infected, apoptotic endothelial cells,
macrophages, and B cells are recognized as “distressed” cells at
local sites of infection and engulfed by LC and iDDC (Ueno et al.,
2007). These DC could then migrate to local lymph nodes while
processing the ingested viral proteins through alternative MHC
class I pathways for presentation to CD8+ T cells. Furthermore,
several HHV-8 proteins, particularly those coded by ORF K3 and
K5, have intriguing properties of altering expression of MHC
class I, T cell coreceptors, and DC-SIGN. Interestingly, cytokines
released by PELs can interfere with the in vitro differentiation
of immature MDDC from CD14+ monocytes (Cirone et al.,
2008).
An intriguing recent discovery is that activated CD4+ T cells
suppress HHV-8 lytic replication in tonsillar B cells (Myoung and
Ganem, 2011a). The suppressive activity requires cell-cell contact.
However, it is not a classic CTL response, as it can be mediated by
T cells from HHV-8 seronegative persons, is not MHC restricted
and does not lyse the B cell targets. This is proposed to be a
pathway by which HHV-8 is driven into latency in B cells. These
CD4+ T cells are reminiscent of CD8+ T cells that exhibit non-
cytotoxic responses that suppress HIV-1 infection (Killian et al.,
2011).
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ALTERED HHV-8 ANTIGEN PROCESSING AND PRESENTATION
Presentation of HHV-8 proteins to both CD8 (MHC class I
restricted) and CD4 (MHC class II restricted) T cells is impaired
by HHV-8 infection. Evidence suggests that anti-HHV-8 CD8+ T
cell responses can be inhibited by K3 and K5 proteins that down-
regulate MHC class I expression (Coscoy and Ganem, 2000;
Ishido et al., 2000b). Interestingly, K5-encoded MIR2 down-
regulates T cell costimulatory molecules ICAM-1 and CD86
(Coscoy and Ganem, 2001) and IFNγR1 (Li et al., 2007b) which
could act to decrease T cell responses to HHV-8. Ishido et al.
showed that K5 also dampens natural killer (NK) cell-mediated
cytotoxicity by downregulation of ICAM-1 and CD86 (Ishido
et al., 2000a). The NK activating receptor, NKG2D, responsi-
ble for detecting infected cells, is downregulated by HHV-8 K5
(Thomas et al., 2008) via the release of the tumor-associated
prostaglandin E2 (PGE2) from KS cells (Dupuy et al., 2012). This
also results in inhibition of IL-15-mediated NK cell activation
and survival, adding to the immune escape tactics employed by
this virus (Dupuy et al., 2012). Likewise, infection of primary
fibroblasts results in limited NK cell activation and killing activity
(Matthews et al., 2011). Brander et al. (2000), reported a decrease
in lysis by HIV-1 peptide-specific CTL clones of cells infected
with HHV-8. Thus, it is apparent that K3 and K5 have multi-
factorial effects on immune control of HHV-8 infection. Of note
is that the intracellular load of HHV-8 in infected endothelial
cells is directly related to their loss of expression of MHC class
I and ICAM-1, in association with expression of MIR2 (Adang
et al., 2007). Interestingly, EBV infection also decreases recogni-
tion of latently infected cells by down regulation of MHC class I
molecules, particularly in cells derived from Burkitt’s lymphoma
(Hislop et al., 2007).
MHC class II recognition is dampened by HHV-8 infection.
Sabbah et al. reported that LCL, with an intact MHC class II pro-
cessing pathway, could present LANA peptides to LANA-specific
CD4+ T cell clones, whereas PEL cells were not recognized in
an IFN-γ ELIspot (Sabbah et al., 2012). PEL express vIRF3, a
known inhibitor of the MHC class II master regulator CIITA
(class II transactivator) (Schmidt et al., 2011). When CIITA func-
tion was restored in PEL, CD4+ T cell clone recognition was also
restored (Sabbah et al., 2012), supporting a role for HHV-8 in
the reduction of MHC class II expression. Interestingly, IFN-γ
inducible expression of CIITA results in MHC class II expres-
sion on endothelial cells, and is impaired after HHV-8 infection
through induction of suppressor of cytokine signaling 3 (SOCS3)
(Butler et al., 2012). This results in inhibition of the early events
in the IFN-γ signaling pathway.
In sum, various HHV-8 proteins appear to play a significant
role in the disruption of antigen processing and presentation.
However, further data are needed to understand the extent of viral
protein function in immunopathogenesis of HHV-8 infection
in APC.
T CELL RESPONSES TO HHV-8: RELATION TO HHV-8 DISEASE
PROGRESSION
Although immunity to HHV-8 is far less well-defined than that
to EBV, T cell immunity to HHV-8 likely plays a similar, criti-
cal role in viral control. First, there is an increase in CD4+ and
CD8+ expanded T cells in patients with classic KS that share a
TCR-β variable subunit bias (Galleu et al., 2012), a phenomenon
observed in response to chronic viral infections (Trautmann et al.,
2005;Wynn et al., 2010). Second, CD8+ T cell immunity to HHV-
8 proteins is present in HHV-8 seropositive, healthy individuals.
CD8+ T cells specific for 5 HHV-8 lytic cycle proteins are present
in blood in the first few months of primary HHV-8 infection of
normal adults (Wang et al., 2001). This primary CTL and IFN-γ
response to HHV-8 peaks within 2 years of infection, and wanes
thereafter to low but detectable levels. Furthermore, KS does not
commonly occur in HIV-1 infected individuals with high CD4+
T cell counts (Strickler et al., 1999).
To date, however, there is little direct evidence for a role of
T cell immunity in HHV-8 infection and control of KS (Hislop
and Sabbah, 2008). Lower CD8+ T cell responses have been
found in persons with KS compared to asymptomatic persons
(Guihot et al., 2006; Lambert et al., 2006). However, very modest
increases in CD8 T cell responses to HHV-8 immunodominant
peptides are found in persons on ART (Wilkinson et al., 2002;
Bourboulia et al., 2004). While progressive increases in HHV-8
load precede development of disease in HIV-1-infected persons
(Campbell et al., 2000; Laney et al., 2007), evidence is lacking for
a direct association between control of HHV-8 load and HHV-
8-specific, T cell immunity (Guihot et al., 2006). Nevertheless,
an increased incidence of KS in organ transplant recipients and
HIV-1-infected persons (Dedicoat and Newton, 2003) suggest
a role for T cell immunity in prevention of KS, similar to T
cell immunity in EBV-related cancers (Gottschalk et al., 2005).
Reduction of immunosuppressive regimens can result in sponta-
neous resolution of KS in organ transplant recipients (Firoozan
et al., 2005). Similarly, the incidence of KS has declined after sup-
pression of HIV-1 by ART (Rabkin, 2001), where T cell numbers
and function are partially restored (Rinaldo et al., 2000; Letvin
and Walker, 2003; Benito et al., 2004). There are also shorter
incubation periods for development of KS after HHV-8 infection
in HIV-1-infected men compared to men infected with HHV-8
prior to HIV-1 infection (Gao et al., 1996; Jacobson et al., 2000).
Primary infection with HHV-8 in immunosuppressed persons
has a more severe outcome than reactivated HHV-8 infection.
Finally, HHV-8 expresses many proteins that have immunomod-
ulatory functions that could down-regulate T cell immunity
(Areste and Blackbourn, 2009).
The emerging biology of KS and HHV-8 infection presents
intriguing factors that interrelate HHV-8-specific T cell immunity
to control of the cancer. HHV-8 is found as a latent infec-
tion in most of the spindle cells in the KS lesion (Moore and
Chang, 1995; Foreman et al., 1997; Dupin et al., 1999; Boshoff
and Chang, 2001). Since replication of herpesviruses in suscep-
tible cells results in cell death, latency must be established either
very soon after infection or possibly following an abortive (non-
productive) infection. A small percentage of endothelial and KS
spindle cells express a complete replication library of HHV-8
proteins early in the disease, whereas the majority of the trans-
formed cells ultimately express only HHV-8 latency proteins.
Circulating B cells and monocytes can be positive for HHV-8
DNA (Ambroziak et al., 1995; Blasig et al., 1997), and HHV-
8-infected macrophages are present in KS tissues (Blasig et al.,
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1997). Th1 cytokines have been implicated in reactivation and
persistence of HHV-8 in B cells and monocytes from KS patients
(Sirianni et al., 1998). T cell infiltrates are common in KS tissues
(Blasig et al., 1997; Fiorelli et al., 1998). CD8+ T cells in KS tissues
produce IFN-γ and express HLA DR (Fiorelli et al., 1998; Sirianni
et al., 1998), suggesting that tumor-infiltrating lymphocytes are
responding to HHV-8 antigens.
Comprehensive longitudinal studies are needed to accurately
assess the role of anti-HHV-8 T cell immunity in development of
KS. T cell responses to HHV-8 could be directed at different lytic
and latency proteins at different stages of infection and disease,
similar to EBV (Gottschalk et al., 2005; Hislop and Sabbah, 2008).
By comparison, the immediate early regulatory protein BMLF1
and other early and late lytic cycle proteins are targets for CD8
CTL during primary and latent EBV infection (Bogedain et al.,
1995; Steven et al., 1997; Hislop et al., 2007).
T CELL RESPONSES TO HHV-8: RELATION TO T CELL RESPONSES TO
EBV
We propose that T cell immunity in EBV infection provides
lessons for what is likely occurring in HHV-8 infection. During
mononucleosis caused by a primary infection with EBV, T cells
specific for both lytic and latency EBV proteins are present, but
responses to lytic epitopes tend to be stronger (Long et al., 2011).
In healthy EBV seropositive individuals, CD8+ T cell responses
are also found to be greater for lytic epitopes, with up to 3%
of cells specific for a single lytic epitope and up to 0.5% for
a single latency epitope (Hislop and Sabbah, 2008). Anti-EBV
CTL responses shift during latent infection to EBV nuclear anti-
gens EBNA3 and LMP2, while still retaining specificity for some
lytic cycle proteins (Hislop et al., 2002). The hierarchy of CTL
responses to immunodominant epitopes of EBV is related to a
lower expression of latency proteins in infected cells (Pudney
et al., 2005). Although HHV-8 does not have genes homologous
to EBNA and LMP, HHV-8 latency-associated nuclear antigen
(LANA or ORF73), kaposin (T0.7 or ORF K12), and K1 are
putative latency and transforming proteins that are targets for
CTL (Osman et al., 1999; Brander et al., 2001; Lepone et al.,
2010).
Host selection of CD8+ T cell epitopes within HHV-8 pro-
teins could be based in part on the relative expression of viral
proteins by the MHC class I endogenous pathway, compara-
ble to EBV (Levitsky et al., 1996). However, evidence from the
anti-EBV CTL field indicates that CTL reactivity to this gamma
herpesvirus varies as to the HLA haplotype, with different MHC
class I haplotypes exhibiting different CTL reactivity to the same
EBV proteins (Hislop et al., 2007). Perhaps HHV-8 has mecha-
nisms similar to the Gly-Ala (Popescu et al., 2003) repeat domain
in EBNA1 that inhibits proteosome processing of viral proteins
through the MHC class I pathway (Levitskaya et al., 1995; Hislop
et al., 2007), thereby inhibiting generation of EBNA1-specific T
cells. In fact, LANA1 can inhibit protein processing in cis (Kwun
et al., 2007; Zaldumbide et al., 2007). Bioinformatic analysis of
HHV-8 sequences supports that latency proteins are likely to be
poorer targets for CTL than immediate early or lytic proteins
(Vider-Shalit et al., 2007). However, it is not yet clear if the in
cis function of LANA1 is directly involved in down-regulation of
CTL lysis of HHV-8 infected cells, including how it compares to
other putative, in trans inhibitors of CTL function such as K3 and
K5.Moreover, the EBNA1-CTL inhibition concept has undergone
major revision. First, the GAr domains of EBNA1 can inhibit
mRNA translation, which may be more critical to lack of CTL
recognition than inhibition of proteosomal processing (Yin et al.,
2003). Second, EBNA1 infected cells express EBNA1 peptides that
can be recognized by CTL when assessed in more sensitive assays
(Lee et al., 2004). This indicates that the effects of LANA1 on
pathways related to CTL function that use chimeric constructs,
indicator cell lines, etc., need to be characterized in a natural con-
text using CD8+ CTL and natural targets that are specific for
LANA1.
Similar to EBV, CD8+ T cell responses to HHV-8 tend to
be directed toward lytic antigens (Robey et al., 2009). While
there are much fewer CD8+ T cell epitopes known for HHV-8
than EBV, the majority of these epitopes are within the early
and late lytic proteins (Robey et al., 2010, 2011). With regard
to polyfunctionality, one study found that for both EBV and
HHV-8, T cells specific for latency antigens were more polyfunc-
tional than those specific for lytic antigens (Bihl et al., 2007b).
The phenotype of these cells was also found to be different,
with a greater proportion of effector memory T cells specific for
latency antigens than lytic antigens for both EBV and HHV-8.
In both EBV and HHV-8-associated malignancies, latency pro-
teins are predominantly expressed, so it is thought that responses
to latency proteins could be important in controlling these dis-
eases (Hislop and Sabbah, 2008; Taylor and Blackbourn, 2011).
Evidence suggests that there are higher levels of CD8+ CTL
specific for EBV and cytomegalovirus (CMV) than HHV-8 in
the blood of seropositive individuals (Wang et al., 2002; Guihot
et al., 2006). Higher T cell responses to EBV and CMV antigens
could be related to their greater viral load in persistently infected
persons, with more turnover of viral antigen from latent, per-
sistent reservoirs that maintains a greater level of memory CTL
precursors.
Antigen-specific CD8+ T cells occupy a lineage of naïve and
memory compartments that are involved in the expansion, effec-
tor, and contraction phases of CD8+ memory T cells (Halwani
et al., 2006). Central memory and effector memory T cells are
contrasted based on expression of surface molecules related to
migration and differentiation. Patients with MCD have more
CD8+CD45RA−CCR7−CD27− IFN-γ+ cells (a late memory T
cell phenotype) and fewer CD8+CD45RA−CCR7−CD27+ cells
(early and intermediate T cell phenotype) than normal, HHV-
8 seropositive controls. This phenotypic shift is not found for
EBV-specific CD8+ T cells. Interestingly, HHV-8 viral loads are
negatively correlated with early and intermediate effector mem-
ory cells. The more differentiated T cell phenotype is associated
with disease, rather than a loss of HHV-8-specific CD8 T cells
or polyfunctional activity, as the HHV-8-specific T cells are sim-
ilar in function (secretion of IFN-γ, TNF-α, MIP1-β, and/or
CD107a) in infected patients and healthy controls (Guihot et al.,
2008).
In healthy, HHV-8 seropositive individuals controlling
infection, there are both monofunctional and polyfunctional
CD8+ T cells present that are specific for HHV-8 proteins
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(Lepone et al., 2010). This could have important implications
in the immunopathogenesis of HHV-8 and for HHV-8-related
disease development. In fact, patients who control KS have
more polyfunctional CD8+ T cells producing IFN-γ and
TNF-α, while patients with progressive KS have weaker and
less polyfunctional HHV-8-specific CD8+ T cells (Bihl et al.,
2009). IFN-γ-producing CTL specific for some HHV-8 lytic
and latency proteins also express CD107 and TNF-α (Bihl et al.,
2007b). This is similar to polyfunctional CTL that produce
multiple cytokines such as IFN-γ, IL-2, and MIP-1β that are
associated with enhanced control of HIV-1 infection (Betts et al.,
2006; Makedonas and Betts, 2006; Streeck et al., 2008). Possibly
relevant to these HHV-8-related factors is that CD8+ CTL
specific for EBV lytic and latency proteins differ in phenotype,
including expression of programmed death-1 (PD-1) (Hislop
et al., 2007). PD-1 expression could act as a negative regulator of
HHV-8-specific CD8+ T cells during disease progression.
While both monofunctional and polyfunctional antiviral
CD8+ T cells are present in healthy HHV-8 seropositive individ-
uals, a week-long DC-enhanced system is required to reveal these
responses to HHV-8 proteins (Wang et al., 2002). Overall, the
immune response to HHV-8 is relatively non-robust compared
to T cell reactivity to other herpesviruses such as EBV (Bihl et al.,
2007b; Lepone et al., 2010). This suggests that the number and/or
functional capacity of circulating anti-HHV-8 T cells are relatively
low. However, using direct staining with multimers of MHC class
I molecules bound to nominal antigens, we have found that there
is an average of 0.05–0.10% circulating, CD8+ T cells specific
for single, immunodominant MHC class I epitopes of HHV-8 in
healthy, HHV-8 seropositive individuals (Lepone et al., 2010).
It is possible that HHV-8-specific T cells are functionally
down-regulated by T regulatory cells (Treg). Treg are operative in
peripheral tolerance and beneficial in preventing autoimmunity
and tissue damage, through such activities as inhibitory cytokine
secretion and suppression of DC function (Vignali et al., 2008).
However, Treg can also inhibit immunity needed to resolve infec-
tions. While little is currently known about Treg during HHV-8
infection and disease development, these cells have been found
to be important during other viral infections, including EBV
(Li et al., 2009) and HIV-1 (Macatangay and Rinaldo, 2010).
During primary EBV infection, patients with mononucleosis have
less Treg than healthy seropositive individuals (Wingate et al.,
2009). In patients with Hodgkin’s lymphoma, Treg accumulated
at tumor sites and those patients with higher Treg ratios had
shorter disease-free survival (Marshall et al., 2004; Schreck et al.,
2009). Additionally in these patients, several EBV epitopes stim-
ulate Treg, and the increases in Treg numbers are associated with
decreased EBV-specific CD8+ T cell IFN-γ production (Marshall
et al., 2007). During HIV-1 infection, HIV-1-specific CD8+ T
cell responses and cytolytic activity are repressed by Treg (Kinter
et al., 2007). Immunotherapy with HIV-1 peptide-loaded MDDC
enhances Treg function, resulting in inhibition of HIV-1 spe-
cific, CD8+ T cell polyfunctionality (Macatangay et al., 2010).
Importantly, this antiviral function can be restored in vitro by
depleting Treg. In patients with nasopharyngeal carcinoma, large
numbers of Treg are found both at tumor sites and in circula-
tion (Lau et al., 2007; Li et al., 2007a). As these cells could also
be important in HHV-8-related disease development such as KS,
studies are needed to determine their exact role.
SUMMARY
Amodio et al. recently showed that the presence of virus-specific
T cells against LANA in classic KS patients was associated with
persistent KS, while K8.1-specific T cells were inversely correlated
with KS occurrence (Amodio et al., 2011). Robey et al. reported a
novel late-lytic glycoprotein ORF28-P29 epitope that was recog-
nized in 7% of HIV+/HHV-8+ individuals (Robey et al., 2011),
compared to an immunodominant HLA A∗0201 late-lytic gly-
coprotein K8.1 (Bourboulia et al., 2004) recognized in 71% by
IFN-γ ELISPOT. Using pentamers, ORF28-P29-specific CD8+ T
cells were determined to have an effector memory phenotype.
Given these results, it appears that T cell responses, in both qual-
ity and magnitude, are essential for control of HHV-8 infection.
Although very intriguing, these studies regarding the presence,
frequency, and phenotype of HHV-8-specific T cells in HHV-
8 infected, and HHV-8/HIV-1 coinfected persons are primarily
cross sectional. This lacks the power of more revealing, multi-
dimensional longitudinal analysis of anti-HHV-8 T cell responses.
For example, it was recently demonstrated that a decline in the
quality of HIV-1-specific CD4+ and CD8+ T cells in HIV-1 infec-
tion, including functional cytokine production, and a shift toward
a memory cell phenotype, occurred over a 7 year period (Dembek
et al., 2012). This evidence supports the need for longitudinal
studies focusing on the reactivity of CD8+ T cells to HHV-8
lytic and latency cycle proteins. We speculate that CD8+ T cell
responses in those individuals that control infection will vary
from those who develop KS. Such studies will provide insight to
the role of these effector responses and how they contribute to the
prevention of KS.
CONCLUSION
To succeed, a pathogen must be able to evade immune surveil-
lance. In this review, we have described the effect of HHV-8 infec-
tion on cells of the immune system, with particular emphasis on
professional APC and the subsequent effect on T cell responses.
Recognition that DC-SIGN expressed on DC, macrophages and
B cells acts as a major receptor for HHV-8 has enhanced our
ability to assess the effect of HHV-8 infection of these primary
cells. This has revealed two distinct replication patterns of HHV-
8 in APC, i.e., non-productive and productive, which could
have direct consequences on viral pathogenesis. Furthermore,
this should enable studies of virus gene transcription cascade in
cells capable of supporting productive infection that are natu-
ral targets of HHV-8. Studies have also begun to elucidate the
effect of HHV-8 infection on DC and B cell functions, as mea-
sured by cytokine and chemokine production and impairment
of antigen presentation. The direct effect of HHV-8 infection
of professional APC and its indirect effect on T cell control of
infection are being tied together in a more revealing fashion to
define the magnitude and breadth of T cell responses to HHV-
8 antigens. T cell responses to HHV-8 antigens are not very
robust as compared to EBV and CMV. The dampened immune
response observed upon HHV-8 infection could be related to
Treg activity. Although evident in HHV-8 infection, it is not clear
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whether polyfunctional T cells are required to control progres-
sion of associated diseases. Given that the most common route
of HHV-8 transmission is through saliva, and that KS lesions
predominate in the skin and mucosa, APC from mucosal sites
are likely to be critical in controlling HHV-8 transmission and
pathogenesis. Understanding how these events are influencing
the ability of APC to induce an effective immune response is
essential in the development of therapeutic and preventative
vaccine strategies.
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